Moreover, recent cost-effective studies showed that the PLASMIC score application on suspected TTP patients during clinical decision-making reduced costs related to unregulated ADAMTS13 activity tests in several institutions [46,47]. This evidence concerns the gene ADAMTS13 and thrombotic thrombocytopenic purpura.